<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 1, 2019 (HealthDay News) — Regardless of test results, 94 percent of women undergoing preimplantation genetic testing for aneuploidy (PGT-A) were satisfied with their decision, according to a study published online June 21 in Human Reproduction<\/i>.<\/p>\n
Kara N. Goldman, from New York University in New York City, and colleagues conducted an anonymous survey of 395 patients who underwent their first cycle of autologous PGT-A between January 2014 and March 2015 at a university-affiliated fertility center.<\/p>\n
Based upon 69 responses, the authors report the respondents most commonly utilized PGT-A on their first IVF cycle to “maximize the efficiency of IVF” or reduce per-transfer miscarriage risk. While the median Brehaut Decision Regret Scale score was low, 39 percent of respondents expressed some degree of regret. Multiple regression analysis showed a relationship between embryo ploidy and decision regret, with a lower number of euploid embryos associated with a greater degree of regret. There was less reported regret among patients who conceived following euploid transfer versus those who miscarried or failed to conceive (P < 0.005). There was no association between decision regret and age, education, race, insurance coverage, religion, marital status or reason for having IVF\/PGT-A, although there was an inverse association with number of living children. There was a negative association between anxiety and age, time since oocyte retrieval, and number of living children.<\/p>\n
“Overall, decision regret was low, and 94 percent of all respondents reported satisfaction with their decision to pursue PGT-A, but patients with a negative outcome were more likely to express decision regret and anxiety,” conclude the authors.<\/p>\n
One author reports ties to the pharmaceutical industry and reproductive medicine institutes.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n